UY34262A - Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos - Google Patents

Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos

Info

Publication number
UY34262A
UY34262A UY0001034262A UY34262A UY34262A UY 34262 A UY34262 A UY 34262A UY 0001034262 A UY0001034262 A UY 0001034262A UY 34262 A UY34262 A UY 34262A UY 34262 A UY34262 A UY 34262A
Authority
UY
Uruguay
Prior art keywords
prepare
compositions
preparation
methods
viral infections
Prior art date
Application number
UY0001034262A
Other languages
English (en)
Inventor
Liu Dazhan
Shi Bing
Wang Fang
Yu Richard Hung Chiu
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46785793&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34262(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of UY34262A publication Critical patent/UY34262A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una forma de hemifumarato de 9 [(R) 2 [[(S) [[(S) 1 (isopropoxicarbonil)etil] amino]fenoxifosfinil]metoxi]propil]adenina (tenofoviralafenamida), sus composiciones, método para su preparación, y la terapia antiviral que utiliza hemifumarato de tenofovir alafenamida (p.ej., las terapias anti HIV y anti HBV), y su uso para preparar medicamentos.
UY0001034262A 2011-08-16 2012-08-15 Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos UY34262A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161524224P 2011-08-16 2011-08-16

Publications (1)

Publication Number Publication Date
UY34262A true UY34262A (es) 2013-04-05

Family

ID=46785793

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034262A UY34262A (es) 2011-08-16 2012-08-15 Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos

Country Status (41)

Country Link
US (2) US8754065B2 (es)
EP (3) EP2744810B2 (es)
JP (5) JP5651275B2 (es)
KR (1) KR101612642B1 (es)
CN (2) CN110343135A (es)
AP (1) AP3639A (es)
AR (1) AR087546A1 (es)
AU (1) AU2012296622C1 (es)
BR (1) BR112014003420B1 (es)
CA (1) CA2845553C (es)
CL (1) CL2014000370A1 (es)
CO (1) CO6880063A2 (es)
CR (1) CR20140072A (es)
CY (1) CY1118385T1 (es)
DK (1) DK2744810T4 (es)
EA (1) EA027768B1 (es)
EC (1) ECSP14013206A (es)
ES (1) ES2608871T5 (es)
FI (1) FI2744810T4 (es)
HK (1) HK1199026A1 (es)
HR (1) HRP20161696T4 (es)
HU (1) HUE031253T2 (es)
IL (2) IL230949A (es)
IN (1) IN2014DN01012A (es)
LT (1) LT2744810T (es)
MA (1) MA35350B1 (es)
MD (1) MD4508C1 (es)
ME (1) ME02612B (es)
MX (1) MX336627B (es)
PE (1) PE20141328A1 (es)
PL (1) PL2744810T5 (es)
PT (1) PT2744810T (es)
RS (1) RS55353B2 (es)
SG (1) SG2014011548A (es)
SI (1) SI2744810T2 (es)
SM (1) SMT201600476B (es)
TW (1) TWI516499B (es)
UA (1) UA115311C2 (es)
UY (1) UY34262A (es)
WO (1) WO2013025788A1 (es)
ZA (1) ZA201400582B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087546A1 (es) 2011-08-16 2014-04-03 Gilead Sciences Inc Hemifumarato de tenofovir alafenamida
KR20200090975A (ko) 2011-10-07 2020-07-29 길리애드 사이언시즈, 인코포레이티드 항-바이러스 뉴클레오티드 유사체의 제조 방법
CN104105484A (zh) * 2012-02-03 2014-10-15 吉联亚科学公司 用于治疗病毒感染的包含替诺福韦艾拉酚胺半反丁烯二酸盐和可比西他的组合疗法
WO2015040640A2 (en) * 2013-09-20 2015-03-26 Laurus Labs Private Limited An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
TWI660965B (zh) * 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
CN105085571A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 替诺福韦艾拉酚胺复合物及其制备方法和用途
CN108148094A (zh) * 2014-11-12 2018-06-12 四川海思科制药有限公司 一种替诺福韦艾拉酚胺富马酸盐晶型c及其制备方法和用途
CN105237571B (zh) * 2014-11-28 2018-03-09 成都苑东生物制药股份有限公司 9‑[(r)‑2‑[[(s)‑[[(s)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐
CN104558036A (zh) * 2014-12-11 2015-04-29 杭州和泽医药科技有限公司 一种替诺福韦艾拉酚胺半反丁烯二酸盐晶型及其制备方法
KR20230130175A (ko) 2014-12-26 2023-09-11 에모리 유니버시티 Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도
EP3240793A1 (en) * 2015-01-03 2017-11-08 Mylan Laboratories Ltd. Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof
CN105669751B (zh) * 2015-03-05 2018-09-21 洛阳聚慧医药科技有限公司 非环核苷酸磷酰胺类化合物及其盐的制备以及在抗病毒方面的应用
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
CZ2015384A3 (cs) 2015-06-05 2016-12-14 Zentiva, K.S. Pevné formy Tenofovir alafenamidu
CA2987085A1 (en) 2015-06-17 2016-12-22 Gilead Sciences, Inc. Co-crystals, salts and solid forms of tenofovir alafenamide
BR112017027843A2 (pt) 2015-06-30 2018-09-04 Gilead Sciences, Inc. formulações farmacêuticas compreendendo tenofovir e emtricitabina
WO2017007701A1 (en) * 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds
TN2018000048A1 (en) 2015-08-10 2019-07-08 Merck Sharp & Dohme Antiviral beta-amino acid ester phosphodiamide compounds
WO2017037608A1 (en) * 2015-08-28 2017-03-09 Laurus Labs Private Limited Solid forms of tenofovir alafenamide and salts thereof, processes for its preparation and pharmaceutical compositions thereof
BR102016026127A2 (pt) 2015-11-09 2017-05-16 Gilead Sciences Inc composições terapêuticas para o tratamento do vírus da imunodeficiência humana
CN106699812A (zh) * 2015-11-12 2017-05-24 江苏豪森药业集团有限公司 替诺福韦前药的制备和纯化方法
WO2017100108A1 (en) 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Antiviral phosphodiamide prodrugs of tenofovir
EP3390413B1 (en) 2015-12-15 2020-08-19 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
ES2806604T3 (es) 2016-02-02 2021-02-18 Sandoz Ag Formas cristalinas de monofumarato de tenofovir alafenamida
CN107226826A (zh) * 2016-03-25 2017-10-03 江苏奥赛康药业股份有限公司 替诺福韦艾拉酚胺富马酸盐化合物及其药物组合物
WO2017203395A1 (en) * 2016-05-21 2017-11-30 Shilpa Medicare Limited Crystalline forms of tenofovir alafenamide hemi fumarate
WO2017211325A1 (zh) 2016-06-05 2017-12-14 上海诚妙医药科技有限公司 富马酸替诺福韦艾拉酚胺盐的新晶型、制备方法及其用途
PE20190910A1 (es) 2016-08-19 2019-06-26 Gilead Sciences Inc Compuestos terapeuticos utiles para el tratamiento profilactico o terapeutico de una infeccion por el virus del vih
EP3503895B1 (en) 2016-08-25 2021-09-15 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
CN107793451A (zh) * 2016-08-30 2018-03-13 江苏奥赛康药业股份有限公司 替诺福韦艾拉酚胺半富马酸盐化合物及其药物组合物
WO2018044822A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
WO2018051250A1 (en) 2016-09-14 2018-03-22 Viiv Healthcare Company Combination comprising tenofovir alafenamide, bictegravir and 3tc
EP3532069A4 (en) 2016-10-26 2020-05-13 Merck Sharp & Dohme Corp. ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS ANTIVIRALS
CN108117570A (zh) * 2016-11-28 2018-06-05 正大天晴药业集团股份有限公司 一种替诺福韦艾拉酚胺半富马酸盐的结晶及其制备方法
CN108129514A (zh) * 2016-12-01 2018-06-08 北京美倍他药物研究有限公司 磷酸/膦酸衍生物的单一异构体及其医药用途
CN108070003A (zh) * 2016-12-02 2018-05-25 上海博志研新药物技术有限公司 替诺福韦艾拉酚胺半反丁烯二酸盐晶型及制备方法和应用
MX2019007585A (es) 2016-12-22 2019-09-09 Merck Sharp & Dohme Profarmacos de ester alifatico antiviricos de tenofovir.
MX2019007262A (es) * 2016-12-22 2019-09-05 Merck Sharp & Dohme Compuestos antivirales de bencilamina fosfodiamida.
EP3560943A4 (en) 2016-12-23 2020-09-02 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NUCLEOSIDIC PHOSPHATE COMPOUND, PROCESS FOR PREPARATION AND USE
WO2018115046A1 (en) 2016-12-23 2018-06-28 Sandoz Ag Crystalline solid forms of tenofovir alafenamide
TWI820984B (zh) * 2017-01-31 2023-11-01 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
WO2018153977A1 (en) 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
CN108794530A (zh) * 2017-04-26 2018-11-13 上海医药工业研究院 一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途
CN107445994A (zh) * 2017-05-31 2017-12-08 北京阜康仁生物制药科技有限公司 替诺福韦艾拉酚胺半富马酸盐新晶型
RU2662160C9 (ru) 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
CN107522743A (zh) * 2017-09-30 2017-12-29 深圳科兴生物工程有限公司 一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法
CN107865874A (zh) * 2017-10-23 2018-04-03 上海博悦生物科技有限公司 一种替诺福韦艾拉酚胺的药物组合物及其制备方法
EP3700573A1 (en) 2017-10-24 2020-09-02 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
AU2018378832B9 (en) 2017-12-07 2021-05-27 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2019130354A1 (en) 2017-12-30 2019-07-04 Cipla Limited Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1- (isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
CA3175557A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
CN108440596B (zh) * 2018-03-22 2020-07-03 科兴生物制药股份有限公司 一种半富马酸替诺福韦艾拉酚胺的新型制备工艺
CN111989335B (zh) 2018-06-12 2023-06-13 四川科伦博泰生物医药股份有限公司 膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途
WO2020018459A1 (en) 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
EP3823629A4 (en) 2018-07-19 2022-05-04 Merck Sharp & Dohme Corp. PHOSPHINAMIDE PRODRUGS OF TENOFOVIR
CA3113011A1 (en) 2018-09-19 2020-03-26 Gilead Sciences, Inc. Integrase inhibitors for the prevention of hiv
KR102054104B1 (ko) * 2019-04-30 2019-12-09 유니셀랩 주식회사 신규한 테노포비어 알라펜아미드 염 및 이의 제조방법
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
CN110452268A (zh) * 2019-08-21 2019-11-15 天地恒一制药股份有限公司 一种丙酚替诺福韦半富马酸单晶的制备方法
EP4065116A1 (en) 2019-11-26 2022-10-05 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
EP4085062A1 (en) * 2020-02-20 2022-11-09 Cipla Limited Novel salts and/or co-crystals of tenofovir alafenamide
AU2021237718B2 (en) 2020-03-20 2023-09-21 Gilead Sciences, Inc. Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
KR20210125298A (ko) 2020-04-08 2021-10-18 주식회사 파마코스텍 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
WO2021262990A1 (en) 2020-06-25 2021-12-30 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
CN116437958A (zh) 2020-11-11 2023-07-14 吉利德科学公司 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法
US11667656B2 (en) 2021-01-27 2023-06-06 Apotex Inc. Crystalline forms of Tenofovir alafenamide
KR20220141457A (ko) 2021-04-13 2022-10-20 경동제약 주식회사 신규 결정형의 테노포비어 알라펜아미드 말레산염 및 이를 포함하는 약제학적 조성물
CA3237155A1 (en) 2021-12-03 2023-06-08 Zhimin Du Therapeutic compounds for hiv virus infection
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
US11787825B2 (en) 2021-12-03 2023-10-17 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TW202402280A (zh) 2022-07-01 2024-01-16 美商基利科學股份有限公司 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302585A (en) * 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
DK0481214T3 (da) 1990-09-14 1999-02-22 Acad Of Science Czech Republic Prolægemidler af phosphonater
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5468768A (en) 1994-01-06 1995-11-21 Bristol-Myers Squibb Company Antimigraine derivatives of indolylcycloalkanylamines
CN101239989B (zh) 1996-07-26 2012-12-12 吉联亚科学股份有限公司 核苷酸类似物
CA2261619C (en) 1996-07-26 2006-05-23 Gilead Sciences, Inc. Nucleotide analogs
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
ATE305009T1 (de) 1997-07-25 2005-10-15 Gilead Sciences Inc Nukleotid-analog zusamensetzung und synthese verfahren
ES2536972T5 (es) 2000-07-21 2022-04-06 Gilead Sciences Inc Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos
MY131488A (en) 2002-04-08 2007-08-30 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
JP2004288898A (ja) * 2003-03-24 2004-10-14 Canon Inc 太陽電池モジュールの製造方法
ECSP045074A (es) 2004-04-22 2004-05-28 Inhibidores hidroxipirimidinona carboxamida n-sustituida de integrasa de vih
EP3287130A1 (en) 2004-05-21 2018-02-28 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and protease inhibitors
WO2007013086A1 (en) 2005-07-26 2007-02-01 Hetero Drugs Limited Novel polymorphs of tenofovir disoproxil fumarate
ES2546378T3 (es) 2006-07-07 2015-09-23 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de agentes terapéuticos
EP2046792B1 (en) * 2006-07-12 2015-02-25 Mylan Laboratories Limited Process for the preparation of tenofovir
EA019893B1 (ru) 2007-02-23 2014-07-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и способ лечения вич-инфекции
EP2160394A1 (en) * 2007-05-22 2010-03-10 Ultimorphix Technologies B.v. Tenofovir disoproxil hemi-fumaric acid co-crystal
MX2010011963A (es) 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
KR101738325B1 (ko) 2009-02-06 2017-05-19 길리애드 사이언시즈, 인코포레이티드 조합 요법용 정제
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
PL2640362T5 (pl) 2010-11-19 2022-05-02 Gilead Sciences, Inc. Kompozycje terapeutyczne zawierające hcl rylpiwiryny i fumaran dizoproksylu tenofowiru
AR087546A1 (es) 2011-08-16 2014-04-03 Gilead Sciences Inc Hemifumarato de tenofovir alafenamida
KR20200090975A (ko) 2011-10-07 2020-07-29 길리애드 사이언시즈, 인코포레이티드 항-바이러스 뉴클레오티드 유사체의 제조 방법
CN104105484A (zh) 2012-02-03 2014-10-15 吉联亚科学公司 用于治疗病毒感染的包含替诺福韦艾拉酚胺半反丁烯二酸盐和可比西他的组合疗法

Also Published As

Publication number Publication date
IN2014DN01012A (es) 2015-05-15
JP2020040972A (ja) 2020-03-19
CA2845553A1 (en) 2013-02-21
HUE031253T2 (en) 2017-07-28
EA201490208A1 (ru) 2014-06-30
ME02612B (me) 2017-06-20
RS55353B2 (sr) 2023-11-30
ECSP14013206A (es) 2014-03-31
AU2012296622B2 (en) 2014-09-11
MD20140011A2 (en) 2014-05-31
EP2744810B1 (en) 2016-10-05
FI2744810T4 (fi) 2023-11-22
JP2014528924A (ja) 2014-10-30
WO2013025788A1 (en) 2013-02-21
JP5651275B2 (ja) 2015-01-07
EP2744810B2 (en) 2023-09-13
US8754065B2 (en) 2014-06-17
ZA201400582B (en) 2017-11-29
IL230949A (en) 2015-09-24
AP3639A (en) 2016-03-13
CA2845553C (en) 2019-05-28
MD4508C1 (ro) 2018-03-31
MX336627B (es) 2016-01-26
TWI516499B (zh) 2016-01-11
JP2018065870A (ja) 2018-04-26
EP3831832A1 (en) 2021-06-09
SI2744810T2 (sl) 2023-11-30
US20140187773A1 (en) 2014-07-03
BR112014003420A2 (pt) 2017-03-01
CY1118385T1 (el) 2017-06-28
ES2608871T5 (es) 2024-04-04
PL2744810T5 (pl) 2024-02-05
HK1199026A1 (en) 2015-06-19
SMT201600476B (it) 2017-03-08
PT2744810T (pt) 2016-11-04
KR20140054068A (ko) 2014-05-08
TW201321396A (zh) 2013-06-01
LT2744810T (lt) 2016-11-25
PL2744810T3 (pl) 2017-04-28
HRP20161696T1 (hr) 2017-02-24
DK2744810T3 (en) 2016-12-05
CN103732594A (zh) 2014-04-16
MX2014001549A (es) 2014-02-27
SI2744810T1 (sl) 2017-01-31
HRP20161696T4 (hr) 2023-10-13
UA115311C2 (uk) 2017-10-25
SG2014011548A (en) 2014-09-26
PE20141328A1 (es) 2014-10-04
US9296769B2 (en) 2016-03-29
EP3070088A1 (en) 2016-09-21
ES2608871T3 (es) 2017-04-17
AU2012296622C1 (en) 2017-02-16
CN110343135A (zh) 2019-10-18
JP2016169228A (ja) 2016-09-23
MD4508B1 (ro) 2017-08-31
AR087546A1 (es) 2014-04-03
US20130065856A1 (en) 2013-03-14
CO6880063A2 (es) 2014-02-28
JP2015038149A (ja) 2015-02-26
NZ620421A (en) 2015-05-29
EP2744810A1 (en) 2014-06-25
CL2014000370A1 (es) 2014-09-05
EA027768B1 (ru) 2017-08-31
AU2012296622A1 (en) 2013-05-09
IL230949A0 (en) 2014-03-31
AP2014007437A0 (en) 2014-02-28
RS55353B1 (sr) 2017-03-31
KR101612642B1 (ko) 2016-04-14
MA35350B1 (fr) 2014-08-01
IL240649A0 (en) 2015-09-24
CR20140072A (es) 2014-06-19
JP6280162B2 (ja) 2018-02-14
DK2744810T4 (da) 2023-11-20
BR112014003420B1 (pt) 2021-07-20
JP5956537B2 (ja) 2016-07-27

Similar Documents

Publication Publication Date Title
UY34262A (es) Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos
UY34100A (es) INMUNOCONJUGADOS DEL PROFARMACO seco-MGBA, COMPOSICIONES Y MÉTODOS PARA PREPARARLOS, Y SUS USOS
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
CR20140175A (es) Compuestos y métodos para mejorar las respuestas inmunitarias innatas
UY34578A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas q ue los contienen
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
CR20140534A (es) Proceso para la preparación de treprostinil y derivado de los mismos
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY34697A (es) Métodos para preparar análogos de nucleótidos
UY33946A (es) Derivados de c4-monometil triterpenoides y sus métodos de uso
CY1120219T1 (el) Ανταγωνιστες της il17c για τη θεραπευτικη αντιμετωπιση φλεγμονωδων διαταραχων
UY34104A (es) ?compuestos derivados benzamídicos heterocíclicos, procesos e intermedios para su preparación, composiciones y métodos para su uso?.
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
UY34306A (es) Pirimidinas condensadas sustituidas y su uso
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
UY34539A (es) Heteroarilos y usos de los mismos
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
UY34234A (es) Inhibidores de la replicación de los virus de la gripe
AR089993A1 (es) Macrociclos peptidomimeticos
NI201300080A (es) Formas sólidas de 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona, y sus composiciones farmacéuticas y usos
EA201490947A1 (ru) Производные пурина для лечения вирусных инфекций
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
UY34764A (es) Derivados de 2,2-difluoropropionamida de metilo de bardoxolona, formas polimórficas y sus métodos de uso
UY34285A (es) Nuevos sulfóxidos de piperidino-dihidrotienopirimidina y su uso para tratar epoc y asma
UY35449A (es) Compuestos heterocíclicos y sus usos

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20200925

110 Patent granted

Effective date: 20240301